Cancerous disease modifying antibodies

Abstract

The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.

1 . Use of monoclonal antibodies for reduction of human lung, pancreatic, ovarian or colon tumor burden, wherein said human lung, pancreatic, ovarian or colon tumor expresses at least one epitope of an antigen which specifically binds to the isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 141205-02 or an antigen binding fragment thereof characterized by an ability to competitively inhibit binding of said isolated monoclonal antibody to its target antigen, comprising administering to said mammal said monoclonal antibody or antigen binding fragment thereof in an amount effective to result in a reduction of said mammal's human lung, pancreatic, ovarian or colon tumor burden. 
     
     
         2 . The method of  claim 1  wherein said isolated monoclonal antibody is conjugated to a cytotoxic moiety. 
     
     
         3 . The method of  claim 2  wherein said cytotoxic moiety is a radioactive isotope. 
     
     
         4 . The method of  claim 1  wherein said isolated monoclonal antibody or antigen binding fragment thereof activates complement. 
     
     
         5 . The method of  claim 1  wherein said isolated monoclonal antibody or antigen binding fragment thereof mediates antibody dependent cellular cytotoxicity. 
     
     
         6 . The method of  claim 1  wherein said isolated monoclonal antibody is a humanized version of the isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 141205-02 or an antigen binding fragment thereof. 
     
     
         7 . The method of  claim 1  wherein said isolated monoclonal antibody is a chimeric antibody of the isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 141205-02 or an antigen binding fragment thereof. 
     
     
         8 . Use of monoclonal antibodies for reduction of human lung, pancreatic, ovarian or colon tumor burden, wherein said human lung, pancreatic, ovarian or colon tumor expresses at least one epitope of an antigen which specifically binds to the isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 141205-02 or an antigen binding fragment thereof characterized by an ability to competitively inhibit binding of said isolated monoclonal antibody to its target antigen, comprising administering to said mammal said monoclonal antibody or antigen binding fragment thereof; in conjunction with at least one chemotherapeutic agent in an amount effective to result in a reduction of said mammal's human lung, pancreatic, ovarian or colon tumor burden. 
     
     
         9 . The method of  claim 8  wherein said isolated monoclonal antibody is conjugated to a cytotoxic moiety. 
     
     
         10 . The method of  claim 9  wherein said cytotoxic moiety is a radioactive isotope. 
     
     
         11 . The method of  claim 8  wherein said isolated monoclonal antibody or antigen binding fragment thereof activates complement. 
     
     
         12 . The method of  claim 8  wherein said isolated monoclonal antibody or antigen binding fragment thereof mediates antibody dependent cellular cytotoxicity. 
     
     
         13 . The method of  claim 8  wherein said isolated monoclonal antibody is a humanized antibody of the isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 141205-02 or an antigen binding fragment produced from said humanized antibody. 
     
     
         14 . The method of  claim 8  wherein said isolated monoclonal antibody is a chimeric antibody of the isolated monoclonal antibody produced by the hybridoma deposited with the IDAC as accession number 141205-02 or an antigen binding fragment produced from said chimeric antibody.